Related Experiment Video
Updated: Jul 7, 2026
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
[Experience with ciclesonide in patients with mild persistent bronchial asthma]
L Bartosíková1, J Necas, L Frána
1Univerzita Palackého, Lékarská fakulta, Ustav fyziologie, Olomouc Dům zdraví, Velké Meziricí. bartosil@tunw.upol.cz
Summary
Ciclesonide effectively treated mild persistent asthma in a 3-month study. Patients experienced improved lung function, reduced symptoms, and better quality of life with no adverse effects.
Area of Science:
- Pulmonology
- Pharmacology
Background:
- Mild persistent bronchial asthma requires effective long-term management.
- Exercise-induced asthma exacerbations impact patient quality of life.
Purpose of the Study:
- To evaluate the efficacy and safety of once-daily ciclesonide (160 microg) in mild persistent asthma.
- To assess the impact of ciclesonide on lung function, symptoms, medication use, and quality of life.
Main Methods:
- A 3-month prospective study involving 100 patients with mild persistent bronchial asthma.
- Daily administration of ciclesonide at a 160 microg dose.
- Evaluation of forced expiratory volume in 1 second (FEV1), peak expiratory flow (PEF), symptom scores, short-acting beta2-sympathomimetic use, and quality of life metrics.
Main Results:
- Significant improvements in FEV1 and PEF values were observed.
- Statistically significant reduction in both daytime and nighttime asthma symptoms.
- Lower consumption of short-acting beta2-sympathomimetics and enhanced quality of life reported.
- No adverse effects were registered during the study period.
Conclusions:
- Once-daily ciclesonide (160 microg) is an effective and safe treatment for mild persistent bronchial asthma.
- Ciclesonide improves lung function, alleviates asthma symptoms, reduces rescue medication needs, and enhances patient quality of life.
Related Concept Videos
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:13Asthma III: Clinical Manifestations
Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:24Asthma-III: Symptoms and Complications
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma